# Exacerbation Risk in Asthma

> **NCT05501639** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1899 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** tiotropium
- **DRUG:** long-acting β2-agonists (LABA)
- **DRUG:** inhaled corticosteroids (ICS)

## Key facts

- **NCT ID:** NCT05501639
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2021-11-02
- **Final completion:** 2021-11-02
- **Target enrollment:** 1899 (ACTUAL)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501639, "Exacerbation Risk in Asthma". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT05501639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*